Advertisement
The new report entitled Rheumatoid Arthritis: Competitive, Crowded MarketSets the Bar High for Novel Agents finds that, through 2016, there are notherapies in development that will displace Enbrel as the clinical goldstandard treatment for rheumatoid arthritis. While some therapies indevelopment for the disease hold promise, most have efficacy, safety andtolerability, and/or delivery features that are inferior when compared withEnbrel.
Advertisement
The overall efficacy of emerging therapies such asCentocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and BiogenIdec/Genentech/Roche's ocrelizumab is comparable to that of Enbrel, while theoverall safety and tolerability for emerging therapies that includeocrelizumab and UCB's Cimzia are also comparable to that of Enbrel. However,the currently available clinical data for golimumab, ocrelizumab and Cimzia isnot as robust or extensive as those available for Enbrel.
"While emerging therapies such as golimumab and Cimzia offer superiordelivery to that of Enbrel due to improved dosing frequencies, these agents'overall efficacy, safety and tolerability, respectively, are inferior to thoseof Enbrel-and efficacy, safety and tolerability are weighted more heavily bysurveyed rheumatologists as key drivers of prescribing decisions," said CindyMundy, Ph.D., director at Decision Resources. "As a result, the improvementsin dosing frequency that golimumab and Cimzia offer over Enbrel are notsufficient to propel either agent to the position of future gold standard."
About the Report
Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High forNovel Agents is a DecisionBase 2008 report from Decision Resources.DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs aredriven by quantitative and qualitative primary research. DecisionBase 2008provides detailed market share, patient share, and price-per-day projectionsfor emerging drugs in development. The market share projections are based onprescriber surveys that compare physicians' expectations of a potential targetproduct profile with an emerging product profile of the leading drugs indevelopment.
The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources, Inc.
